Become an IMR Panelist
IMR Logo

Neuromodulation Devices Market Size, Share, Growth & Forecast (2024-2032)

Neuromodulation Devices Market Global Industry Analysis and Forecast (2024-2032) by Product (Spinal Cord Stimulation (SCS) Devices, Deep Brain Stimulation (DBS) Devices, Sacral Nerve Stimulation (SNS) Devices, Vagus Nerve Stimulation (VNS) Devices, Transcranial Magnetic Stimulation (TMS) Devices, Other Neuromodulation Devices), Technology (Invasive Neuromodulation Devices, Non-Invasive Neuromodulation Devices), Application (Chronic Pain, Parkinson's Disease, Epilepsy, Depression, Alzheimer???s Disease, Urinary Incontinence, Others), End User (Hospitals, Ambulatory Surgical Centers, Home Care Settings, Clinics) and Region

  • Report ID : 20434
  • Category : Medical Devices
  • Format :Excel formatPDF formatWord format
Request Sample

Neuromodulation Devices Market Synopsis:

Neuromodulation Devices Market Size Was Valued at USD 5.34 Billion in 2023, and is Projected to Reach USD 12.48 Billion by 2032, Growing at a CAGR of 9.90% From 2024-2032.

Neuromodulation devices market is defined as the field that deals with the manufacturing and marketing of medical devices that is used to affect the activity of the nerves either mechanically by electrical signals or by using certain chemicals. These devices are employed for management of a number of neurological disorders ranging from chronic pain, Parkinson’s disease, epilepsy, depression and incontinence to provide patients with minimized invasive therapeutic solutions. The market is driven by such factors as continuous developments in technology, and the design of the device used in neuromodulation therapies, and heightened awareness of the neuromodulation therapy as compared to other standard therapies.

One of the big drivers that helped the neuromodulation devices market evolve were neurological and chronic pain disorders market. They include; Management of diseases like Parkinson, epilepsy, and chronic pain that are increasing globally needs a smart way to handle. As traditional approaches wherein medications and operations may not be very efficient or as they sometimes are associated with adverse effects, neuromodulation devices are gradually emerging as possible solutions of choice due to a relatively low risk of complications and longer overall therapeutic outcomes.

Another micro factor that can be said to have a direct effect on the operation market is the technological factor. Newer parameter aspects in MRI guided, broadband based therapy methods such as TMS and fine adjustments of invasive tools as DBS are sharpening up the treatment. About the same way, they are trying to style neuromodulation therapies as appealing and easily accessible, and therefore are enhancing the market potential.

Neuromodulation Devices Market Trend Analysis:

Growing shift towards non-invasive and minimally invasive therapies

  • One of the ongoing trends in the market of the neuromodulation devices is the rising focus on non-invasive and minimal invasive treatments. Noninvasive procedures such as TMS and tDCS have shown increased use as they do not predispose the patient to serious side effects seen with invasive procedures. The reason why patients and healthcare providers prefer such techniques is that they provide enormous therapeutic advantages with little down time.
  • The other trend is the incorporation of the neuromodulation devices with other technologies like artificial intelligence AI, and wearables. It has been used for conforming to the bespoke care pathways, likely patient reactions and even calibrating the functioning of devices. This technological complementarity is improving the accuracy and efficiency of the primary neuromodulation therapies thereby increasing the utilization of the therapy.

Healthcare infrastructure improvements and rising healthcare expenditures

  • Market growth in the neuromodulation devices industry provides one of the market’s major opportunities in emerging markets with Asia-Pacific and Latin America. These are becoming essential as a number of advanced medical devices are on demand due to progressing healthcare infrastructure and rising expenditures on health care in these regions. Such opportunities may be captured by companies through localisation of their products, and entering into liaison with regional health care institutions.
  • At the same time, opening up the possibilities for the use of neuromodulation therapy in the treatment of other diseases is a new networking opportunity for market participants. Although neuromodulation devices at the moment are applied for chronic pain, Parkinson’s disease, epilepsy among others there is research on how the devices can be used in conditions such as depression, Alzheimer’s disease, and anxiety. The further expansion of the indications spectrum will expand the market’s reach to a great extent.

Neuromodulation Devices Market Segment Analysis:

Neuromodulation Devices Market is Segmented on the basis of Product, Technology, Application, End User, and Region

By Product, Spinal Cord Stimulation (SCS) Devices segment is expected to dominate the market during the forecast period

  • Neuromodulation device markets segmentation by product type is currently designed with several advanced therapeutic products that can treat various neurological disorders. The Spinal Cord Stimulation (SCS) is implantable devices for pain control, which sends electrical signals to the spinal nerves. DBS devices are put in a specific part of the brain to acknowledged medical conditions such as Parkinson’s disease or epilepsy. It is a kind of implants that are used to control urinary incontinence by electrical impulse stimulation of nerve.” Vagus Nerve Stimulators also known as VNS are implanted medical devices for neurologically prescribed epilepsy and/or depression by producing electrical signals to the vagus nerve. TMS equipment is used in prescribing treatment for disorders like depression by means of subjecting the nervous tissues of the head to the application of magnetic field. These other neuromodulation devices incorporate a number of new technologies and approaches aimed at expanding the range of neurmodulation options.

By Application, Chronic Pain segment expected to held the largest share

  • The market is also classified on the basis of application which provides a solution for neurological as well as, chronic diseases. One can illustrate this by taking cancer cases where neurostimulation equipment including SCS spinal stimulators are normally used to control such pain as; back/neck pain, Neuropathic pain among others. The deep brain stimulators are employed in the management of Parkinson’s disease through managing the motor signs through the stimulation of some parts of the brain. Another one is epilepsy; where devices including; Lev Vagus Nerve Stimulation (VNS) and deep Brain Simulators have been effectively used to control the seizures. Today, a severe medical disorder like depression is resolved through a simple procedure that employs the Transcranial Magnetic Stimulation (TMS) gadgets. Neuromodulation devices also assist with Alzheimer’s disease and cognitive disorders, and further investigations have to be carried out to determine the effectiveness of outcomes as well. The Urinary incontinence is managed through Sacral Nerve Stimulation (SNS) these are the nerves responsible for the control of bladders. There are some other functions in other neurological disorders, psychotic and other disorders and some other new functions which includes anxiety and migraine.

Neuromodulation Devices Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

  • North America region holds the largest avenue of the neuromodulation devices market led by the positive adoption trend of the improved medical technologies in the U.S. and Canada. Some of these are the pressure from key players in the region, particularly due to the reimbursement policies and a sound health care structure that has placed this region at the forefront. In addition, an increasing incidence in neurological disorders and enhanced knowledge of minimally invasive treatment approaches give a boost to North America as well.
  • The U.S. healthcare is especially concerned with innovation, and thus, a numerous amount of works has been done in the field of neuromodulation technologies. This has made the market grow fast because there have been many clinical trials and success product launch in the recent past. Thus, North America remains in the leading positions and is expected to dominate the market in the coming years.

Active Key Players in the Neuromodulation Devices Market:

  • Abbott Laboratories (U.S.)
  • Boston Scientific Corporation (U.S.)
  • Cyberonics, Inc. (U.S.)
  • ElectroCore, Inc. (U.S.)
  • LivaNova PLC (U.K.)
  • Medtronic (Ireland)
  • Nevro Corporation (U.S.)
  • Nuvectra Corporation (U.S.)
  • St. Jude Medical (U.S.)
  • Synapse Biomedical Inc. (U.S.)
  • Other Active Players

Global Neuromodulation Devices Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 5.34 Billion

Forecast Period 2024-32 CAGR:

 9.90%

Market Size in 2032:

USD 12.48 Billion

Segments Covered:

By Product
  • Spinal Cord Stimulation (SCS) Devices
  • Deep Brain Stimulation (DBS) Devices
  • Sacral Nerve Stimulation (SNS) Devices
  • Vagus Nerve Stimulation (VNS) Devices
  • Transcranial Magnetic Stimulation (TMS) Devices
  • Other Neuromodulation Devices

By Technology
  • Invasive Neuromodulation Devices
  • Non-Invasive Neuromodulation Devices

By Application
  • Chronic Pain
  • Parkinson's Disease
  • Epilepsy
  • Depression
  • Alzheimer’s Disease
  • Urinary Incontinence
  • Others

By End user
  • Hospitals
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Clinics

By Region
  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC)
  • Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:
  • Advancements in Non-Invasive and Minimally Invasive Technologies

Key Market Restraints:
  • High Initial Costs and Limited Insurance Coverage

Key Opportunities:
  • Development of New Applications for Neuromodulation Devices

Companies Covered in the report:
  • Medtronic (Ireland), Boston Scientific Corporation (U.S.), Abbott Laboratories (U.S.), Nevro Corporation (U.S.), Nuvectra Corporation (U.S.), Cyberonics, Inc. (U.S.), LivaNova PLC (U.K.), St. Jude Medical (U.S.), ElectroCore, Inc. (U.S.), Synapse Biomedical Inc. (U.S.), and Other Active Players.

Frequently Asked Questions :

What would be the forecast period in the Neuromodulation Devices Market research report?
The forecast period in the Neuromodulation Devices Market research report is 2024-2032.
Who are the key players in the Neuromodulation Devices Market?
Medtronic (Ireland), Boston Scientific Corporation (U.S.), Abbott Laboratories (U.S.), Nevro Corporation (U.S.), Nuvectra Corporation (U.S.), Cyberonics, Inc. (U.S.), LivaNova PLC (U.K.), St. Jude Medical (U.S.), ElectroCore, Inc. (U.S.), Synapse Biomedical Inc. (U.S.) and Other Active Players.
What are the segments of the Neuromodulation Devices Market?
The Neuromodulation Devices Market is segmented into by Product (Spinal Cord Stimulation (SCS) Devices, Deep Brain Stimulation (DBS) Devices, Sacral Nerve Stimulation (SNS) Devices, Vagus Nerve Stimulation (VNS) Devices, Transcranial Magnetic Stimulation (TMS) Devices, Other Neuromodulation Devices), Technology (Invasive Neuromodulation Devices, Non-Invasive Neuromodulation Devices), Application (Chronic Pain, Parkinson's Disease, Epilepsy, Depression, Alzheimer???s Disease, Urinary Incontinence, Others), End User (Hospitals, Ambulatory Surgical Centers, Home Care Settings, Clinics). By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, The Netherlands, Italy, Russia, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
What is the Neuromodulation Devices Market?
The neuromodulation devices market refers to the industry focused on the development and commercialization of medical devices that modulate nerve activity through electrical stimulation or chemical agents. These devices are used to treat a variety of neurological conditions, including chronic pain, Parkinson???s disease, epilepsy, depression, and incontinence, offering patients non-invasive or minimally invasive therapeutic options. The market is driven by technological advancements in device design and increasing awareness of neuromodulation therapies as an alternative to traditional treatment methods.
How big is the Neuromodulation Devices Market?
Neuromodulation Devices Market Size Was Valued at USD 5.34 Billion in 2023, and is Projected to Reach USD 12.48 Billion by 2032, Growing at a CAGR of 9.90% From 2024-2032.
Request Sample

Related Reports

Services Designed to Meet Your Priorities

Understand your customers' needs so can deliver better services and experiences.

Show more

Subscribe to our Newsletter

Stay in touch with us to get latest news and discount coupons.